Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Nonalcoholic Steatohepatitis (NASH): KOL Insight Update Bulletin [December 2016]

Product Code:
596200610
Publication Date:
December 2016
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of nonalcoholic steatohepatitis (NASH). Topics covered include expert opinions on the positive Phase II data reported for Gilead’s selonsertib (GS-4997) in NASH patients with fibrosis. KOLs discuss the implications of these results and Gilead’s decision to terminate clinical development of simtuzumab in NASH. Experts cover the recent results from the NASH-FX study for Galectin Therapeutics’ GR-MD-02 and whether this drug has a future in NASH. KOLs also offer their opinions on novel early-stage mechanisms, such as Shire’s volixibat (SHP626), Gilead/Nimbus Therapeutics’ NDI 010976 and Bristol-Myers Squibb’s (BMS’) BMS 986036.

  • What is the consensus on the positive Phase II data reported for Gilead’s selonsertib and simtuzumab combination?
  • How do KOLs view the improvements in fibrosis reported for the combination compared to other drugs?
  • Do experts have any major safety concerns about MAP kinase inhibition?
  • What do the experts think about Gilead’s decision to terminate clinical development of simtuzumab in NASH?
  • How do the KOLs view the failure of Galectin Therapeutics’ NASH-FX study and what could have been done differently?
  • Does GR-MD-02 have any future potential and what are KOL expectations for the NASH-CX study which is due to complete in 2017?
  • What are KOL opinions on novel mechanisms of action such as, Shire’s volixibat, Gilead/Nimbus’ NDI 010976 and BMS’ BMS 986036?
  • Why are some specialists enthusiastic about using anti-diabetic drugs in NASH?



customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved